Health
FDA Dispute Over Blood Pressure Feature
Whoop and the FDA are in discussions following a warning letter over a controversial blood pressure feature. The dispute highlights ongoing tensions between tech companies and regulatory bodies.
Coverage timeline — 2 articles
STAT News
STAT+: After warning letter, Whoop and FDA in discussions about controversial blood pressure feature
Whoop is yet to resolve a dispute with the FDA over a blood pressure feature, a top executive said at STAT's Breakthrough Summit.
2026-05-21 08:30 UTC
STAT News
It almost feels like the Trump administration is intentionally breaking the FDA, writes Lab Dish columnist Paul Knoepfler.
2026-05-21 08:30 UTC